MedPath

SPECT/CT in Endocrine and Neuroendocrine Tumors

Not Applicable
Completed
Conditions
Endocrine and Neuroendocrine Tumors
Registration Number
NCT00230139
Lead Sponsor
Rambam Health Care Campus
Brief Summary

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

Detailed Description

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors.
  • Patient signed informed consent
Exclusion Criteria
  • The study will not be performed in pregnant or lactating women.
  • Patient will not be able or willing to tolerate the scan until its completion.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
The impact of imaging modality on patient management
Secondary Outcome Measures
NameTimeMethod
The impact of imaging modality on patient management

Trial Locations

Locations (1)

Rambam Medical Center

🇮🇱

Haifa, Israel

© Copyright 2025. All Rights Reserved by MedPath